Phathom Pharmaceuticals (PHAT) Cash from Operations (2018 - 2026)
Phathom Pharmaceuticals (PHAT) reported Cash from Operations of 15647000.0 for Q1 2026, up 81.58% year-over-year from 8617300.16 in Q1 2025, and down 212.88% quarter-over-quarter from 5001000.0 in Q4 2025.
Phathom Pharmaceuticals (PHAT) Cash from Operations (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Cash from Operations data on file, last reported at 15647000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 15647000.0, up 81.58% year-over-year; the trailing twelve-month figure through Mar 2026 was 97492000.0 (up 65.51% YoY), and the FY2025 annual result was 166775000.0, up 37.48% from the prior year.
- Cash from Operations declined to 15647000.0 in Q1 2026 per PHAT's latest filing, from 5001000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 5001000.0 in Q4 2025 and troughed at 84930000.0 in Q1 2025.
- A 5-year average of 43135411.76 and a median of 41041000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations plunged 218.56% in 2024, then surged 92.12% in 2025.
- A 5-year view of Cash from Operations shows it stood at 41041000.0 in 2022, then declined by 6.72% to 43797000.0 in 2023, then plunged by 44.89% to 63456000.0 in 2024, then surged by 92.12% to 5001000.0 in 2025, then plunged by 212.88% to 15647000.0 in 2026.
- Business Quant data shows PHAT's Cash from Operations at 15647000.0 in Q1 2026, 5001000.0 in Q4 2025, and 14115000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -15.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.65 Mn |
| Mar 31, 2026 | -15.65 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Sep 30, 2025 | -14.12 Mn |
| Sep 30, 2025 | -14.12 Mn |
| Jun 30, 2025 | -62.73 Mn |
| Jun 30, 2025 | -62.73 Mn |
| Mar 31, 2025 | -84.93 Mn |
| Mar 31, 2025 | -84.93 Mn |
| Dec 31, 2024 | -63.46 Mn |
| Dec 31, 2024 | -63.46 Mn |
| Sep 30, 2024 | -63.57 Mn |
| Sep 30, 2024 | -63.57 Mn |
| Jun 30, 2024 | -70.72 Mn |
| Jun 30, 2024 | -70.72 Mn |
| Mar 31, 2024 | -69.02 Mn |
| Mar 31, 2024 | -69.02 Mn |
| Dec 31, 2023 | -43.80 Mn |
| Dec 31, 2023 | -43.80 Mn |